Table 1.

Patient characteristics

Patient ID	Age (years)	Gender	Smoking status (pack-year)	HPV status	PD-L1 CPS	PD-L1 TPS	Primary location	Clinical TNM	Sitravatinib (days)	Nivolumab dosed	Surgery within window	Pathologic TNM	PTR (% of viable tumor)	Margins (>5 mm)	ENE	PORT
S-001	58	Male	Never	Negative	>20	>50	Alveolus	cT4aN2b	21	Yes	Yes	ypT0N0	cPR (0)	Negative	No	Yes
S-002	58	Female	Never	Negative	>20	>50	Alveolus	cT4aN2b	21	Yes	Yes	ypT4aN0*	mPR (<10)	Negative	No	Yes
S-004	59	Male	Current (30)	Negative	>20	1–50	Tongue	cT3N1	28	Yes	Yes	ypT2N0	iPR (65)	Negative	No	Yes
S-006	59	Male	Former (40)	Negative	>20	1–50	Tongue	cT3N1	21	Yes	Yes	ypT3N1	iPR (36)	Negative	No	Yes
S-007	63	Male	Current (50)	Negative	<1	<1	Floor of mouth	cT4aN2c	21	Yes	Yes	ypT4aN0	iPR (94)	Negative	No	Yes
S-008	60	Male	Former (30)	Negative	1–20	1–50	Tongue	cT2N0	21	Yes	Yes	ypT1pN0	iPR (100)†	Negative	No	No
S-009	71	Female	Never	Negative	>20	1–50	Alveolus	cT4aN1	15	Yes	No	ypT3pN0	iPR (95)	Negative	No	Yes
S-010	68	Male	Former (20)	Positive	1–20	1–50	Tongue	cT2N2b	28	Yes	Yes	ypT1pN2a	iPR (38)	Negative	No	Yes
S-011	50	Male	Current (40)	Negative	1–20	<1	Tongue	cT3N0	28	Yes	Yes	ypT1pN1	iPR (87)	Negative	No	Yes
S-013	53	Male	Never	Negative	>20	1–50	Alveolus	cT4aN0	28	Yes	Yes	ypT2pN0‡	mPR (<10)	Negative	No	Yes

*No invasive squamous cell carcinoma found in the mucosa, only remaining focis in the bone.

†iPR (100): this patient’s surgical specimen had residual viable tumor in all the areas evaluated.

‡Prominent lymphohistiocytic inflammatory infiltrate with multiple giant cells and cholesterol cleft, which involve the soft tissue underneath the mucosa extensively. Remaining 1 cm tumor is also heavily ulcerated with prominent inflammatory infiltrate.

CPS, combined positive score; ENE, extranodal extension; HPV, human papillomavirus; ID, identification; PD-L1, programmed ligand-1; PORT, postoperative radiotherapy; PTR, pathological treatment response; TNM, tumor-node-metastasis classification; TPS, tumor positive score.